Literature DB >> 16553916

Serotype distribution and antibiotic susceptibility of invasive and nasopharyngeal isolates of Streptococcus pneumoniae among children in rural Mozambique.

Xavier Vallès1, Brendan Flannery, Anna Roca, Inacio Mandomando, Betuel Sigaúque, Sergi Sanz, Anne Schuchat, Myron Levine, Montserrat Soriano-Gabarró, Pedro Alonso.   

Abstract

OBJECTIVE: To describe and compare serotype distribution and antibiotic susceptibility of invasive and nasopharyngeal isolates of Streptococcus pneumoniae from children in rural Mozambique.
METHODS: From August 2002 to July 2003, we prospectively obtained invasive pneumococcal isolates from children <15 years of age admitted to the paediatric ward of Manhiça District Hospital. During a cross-sectional study of children <5 years of age with mild illnesses, attending the outpatient department of the hospital in March and April 2003, we collected nasopharyngeal isolates. Serotypes and antibiotic susceptibilities were determined using standardized methods.
RESULTS: The two most common pneumococcal serotypes among invasive isolates were types 1 (40% of 88 isolates serotyped) and 5 (10%), but these types were rare among nasopharyngeal isolates. Compared with invasive isolates, nasopharyngeal isolates were more likely to be serotypes in the licensed seven-valent conjugate vaccine (49%vs. 20%, P < 0.01), to have intermediate-level penicillin resistance (52%vs. 14%, P < 0.01) and to be non-susceptible to trimethoprim-sulfamethoxazole (61%vs. 45%, P < 0.01). Recent receipt of antibiotics or sulfadoxine/pyrimethamine were associated with carriage of antibiotic non-susceptible isolates.
CONCLUSIONS: These data indicate that a pneumococcal conjugate vaccine containing serotypes 1 and 5 could substantially reduce pneumococcal invasive disease among young children in rural Mozambique. Carriage surveys can overestimate potential coverage of the seven-valent pneumococcal conjugate vaccine in settings where serotypes 1 and 5 predominate.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16553916     DOI: 10.1111/j.1365-3156.2006.01565.x

Source DB:  PubMed          Journal:  Trop Med Int Health        ISSN: 1360-2276            Impact factor:   2.622


  26 in total

1.  Antimicrobial drug resistance trends of bacteremia isolates in a rural hospital in southern Mozambique.

Authors:  Inácio Mandomando; Betuel Sigaúque; Luis Morais; Mateu Espasa; Xavier Vallès; Jahit Sacarlal; Eusébio Macete; Pedro Aide; Llorenç Quintò; Tacilta Nhampossa; Sónia Machevo; Quique Bassat; Clara Menéndez; Joaquim Ruiz; Anna Roca; Pedro L Alonso
Journal:  Am J Trop Med Hyg       Date:  2010-07       Impact factor: 2.345

2.  Genotypic analysis of invasive Streptococcus pneumoniae from Mali, Africa, by semiautomated repetitive-element PCR and pulsed-field gel electrophoresis.

Authors:  S M Harrington; F Stock; A L Kominski; J D Campbell; J C Hormazabal; S Livio; L Rao; K L Kotloff; S O Sow; P R Murray
Journal:  J Clin Microbiol       Date:  2006-12-27       Impact factor: 5.948

3.  Distinguishing malaria from severe pneumonia among hospitalized children who fulfilled integrated management of childhood illness criteria for both diseases: a hospital-based study in Mozambique.

Authors:  Quique Bassat; Sónia Machevo; Cristina O'Callaghan-Gordo; Betuel Sigaúque; Luís Morais; Núria Díez-Padrisa; Josep L Ribó; Inácio Mandomando; Tacilta Nhampossa; Edgar Ayala; Sergi Sanz; Martin Weber; Anna Roca; Pedro L Alonso
Journal:  Am J Trop Med Hyg       Date:  2011-10       Impact factor: 2.345

Review 4.  Multidrug-resistant Streptococcus pneumoniae infections: current and future therapeutic options.

Authors:  Françoise Van Bambeke; René R Reinert; Peter C Appelbaum; Paul M Tulkens; Willy E Peetermans
Journal:  Drugs       Date:  2007       Impact factor: 9.546

5.  Procalcitonin and C-reactive protein for invasive bacterial pneumonia diagnosis among children in Mozambique, a malaria-endemic area.

Authors:  Núria Díez-Padrisa; Quique Bassat; Sonia Machevo; Llorenç Quintó; Luis Morais; Tacilta Nhampossa; Cristina O'Callaghan-Gordo; Antoni Torres; Pedro L Alonso; Anna Roca
Journal:  PLoS One       Date:  2010-10-14       Impact factor: 3.240

6.  The descriptive epidemiology of Streptococcus pneumoniae and Haemophilus influenzae nasopharyngeal carriage in children and adults in Kilifi district, Kenya.

Authors:  Osman Abdullahi; Joyce Nyiro; Pole Lewa; Mary Slack; J Anthony G Scott
Journal:  Pediatr Infect Dis J       Date:  2008-01       Impact factor: 2.129

7.  Age-specific cluster of cases of serotype 1 Streptococcus pneumoniae carriage in remote indigenous communities in Australia.

Authors:  H Smith-Vaughan; R Marsh; G Mackenzie; J Fisher; P S Morris; K Hare; G McCallum; M Binks; D Murphy; G Lum; H Cook; V Krause; S Jacups; A J Leach
Journal:  Clin Vaccine Immunol       Date:  2008-12-17

Review 8.  Biological and Epidemiological Features of Antibiotic-Resistant Streptococcus pneumoniae in Pre- and Post-Conjugate Vaccine Eras: a United States Perspective.

Authors:  Lindsay Kim; Lesley McGee; Sara Tomczyk; Bernard Beall
Journal:  Clin Microbiol Rev       Date:  2016-07       Impact factor: 26.132

9.  Challenges in the diagnosis of iron deficiency in children exposed to high prevalence of infections.

Authors:  Ruth Aguilar; Cinta Moraleda; Llorenç Quintó; Montse Renom; Lázaro Mussacate; Eusebio Macete; Josep L Aguilar; Pedro L Alonso; Clara Menéndez
Journal:  PLoS One       Date:  2012-11-27       Impact factor: 3.240

10.  A pragmatic health centre-based evaluation comparing the effectiveness of a PCV13 schedule change from 3+0 to 2+1 in a high pneumococcal carriage and disease burden setting in Malawi: a study protocol.

Authors:  Todd D Swarthout; Ana Ibarz-Pavon; Gift Kawalazira; George Sinjani; James Chirombo; Andrea Gori; Peter Chalusa; Farouck Bonomali; Roseline Nyirenda; Edwin Bulla; Comfort Brown; Jacquline Msefula; Marjory Banda; Jean Kachala; Charles Mwansambo; Marc Yr Henrion; Stephen B Gordon; Neil French; Robert S Heyderman
Journal:  BMJ Open       Date:  2021-06-17       Impact factor: 2.692

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.